Patent · US Active

Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases

US9394290B2 · kind B2 · utility

5Cited by

3References

7Claims

0Family size

Assignee

UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN · DE

Inventors

Rolf Hartmann · Saarburg, DE
Ulrike Hille · Soest, DE
Christina Zimmer · Völklingen, DE
Carsten A. Vock · Friedland, DE
Qingzhong Hu · Riegelsberg, DE

Key dates

Filing date	Oct 21, 2011
Grant date	Jul 19, 2016
Priority date	—
Expiry date	Oct 21, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.